Mineralys Therapeutics 2022: Aldosterone Treatment Hypertension

Mineralys Therapeutics presented its clinical-stage development of lorundrostat, a selective aldosterone synthase inhibitor for hypertension treatment. The compound demonstrated significant blood pressure reductions of 9.1–10.0 mmHg in uncontrolled and resistant hypertension patients, with a favorable safety profile and rapid reversibility. Mineralys holds worldwide rights to lorundrostat through 2035 and plans to advance the asset into pivotal development.